Stefan Smesny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stefan Smesny has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Heinrich Sauer
Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany
17 shared publications- Gunther Paul Amminger
Australia and Centre for Youth Mental Health University of Melbourne Melbourne Australia
11 shared publications Berko Milleit
Department of Psychiatry, University Hospital Jena, Philosophenweg 3, D-07743 Jena, Germany
7 shared publicationsKerstin Langbein
Department of Psychiatry, Jena University Hospital, Jena, Germany
7 shared publicationsAlexander Gussew
Department of Medical Physics, University Hospital Halle (Saale), Halle (Saale), Germany
5 shared publicationsIgor Nenadic
Department of Psychiatry, Jena University Hospital, Philosophenweg 3, D-07743 Jena, Germany
5 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by Springer Nature in Borderline Personality Disorder and Emotion Dysregulation
- Vol. 12 (1) , 48
Emotion-focused vs. cognitive interventions of schema therapy for borderline personality disorder: effects on neural emotion regulation networks - study protocol
Background: While the effects of psychotherapy methods are being intensively researched, little is known about the clinical and neurobiological effects of specific psychotherapeutic interventions. This study examines the effects of experiential emotion-focused and cognitive interventions in schema therapy on emotion regulation in borderline personality disorder. Methods: In a randomized, single-blinded, parallel group design, clinical effects and effects on resting-state functional connectivity in neural emotion regulation networks and neurotransmitter metabolism (Glx/GABA) in key regions of these networks are compared. The 9-week treatment protocol includes emotion-focused interventions such as chair dialogues, imagery rescripting, or mode role-playing in the test condition; these interventions are omitted in the active control condition (dismantling design). Resting-state functional MR imaging (rsfMRI) and MEGA-sLASER 1 H MR spectroscopy in the pregenual cingulate cortex (pgACC), anteromedial cingulate cortex (aMCC), and dorsolateral prefrontal cortex (DLPFC) are performed before and after the therapy interval and 6 months after the end of therapy and compared with the neurobiological parameters of healthy control subjects. The clinical effects are recorded using a comprehensive test battery and specified using the Reliable Change Index (RCI). Clinical and biological data are examined using mixed model analysis both longitudinally and in terms of their interactions. Discussion: The aim is to show that different psychotherapeutic interventions have different effects on deficits in emotion regulation associated with specific effects on neural emotion regulation networks. This would contribute to a better understanding of the neurobiological effects and mechanisms underlying psychotherapeutic core interventions and to their more targeted use in BPD and other related disorders in the future. Trial registration: ClinicalTrials.gov Identifier: NCT06367907, Retrospectively registered, April 2024.
- 13 November 2025
- Published by Springer Nature in Borderline Personality Disorder and Emotion Dysregulation
- Vol. 12 (1) , 48
Open AccessEmotion-focused vs. cognitive interventions of schema therapy for borderline personality disorder: effects on neural emotion regulation networks - study protocol
Background: While the effects of psychotherapy methods are being intensively researched, little is known about the clinical and neurobiological effects of specific psychotherapeutic interventions. This study examines the effects of experiential emotion-focused and cognitive interventions in schema therapy on emotion regulation in borderline personality disorder. Methods: In a randomized, single-blinded, parallel group design, clinical effects and effects on resting-state functional connectivity in neural emotion regulation networks and neurotransmitter metabolism (Glx/GABA) in key regions of these networks are compared. The 9-week treatment protocol includes emotion-focused interventions such as chair dialogues, imagery rescripting, or mode role-playing in the test condition; these interventions are omitted in the active control condition (dismantling design). Resting-state functional MR imaging (rsfMRI) and MEGA-sLASER 1 H MR spectroscopy in the pregenual cingulate cortex (pgACC), anteromedial cingulate cortex (aMCC), and dorsolateral prefrontal cortex (DLPFC) are performed before and after the therapy interval and 6 months after the end of therapy and compared with the neurobiological parameters of healthy control subjects. The clinical effects are recorded using a comprehensive test battery and specified using the Reliable Change Index (RCI). Clinical and biological data are examined using mixed model analysis both longitudinally and in terms of their interactions. Discussion: The aim is to show that different psychotherapeutic interventions have different effects on deficits in emotion regulation associated with specific effects on neural emotion regulation networks. This would contribute to a better understanding of the neurobiological effects and mechanisms underlying psychotherapeutic core interventions and to their more targeted use in BPD and other related disorders in the future. Trial registration: ClinicalTrials.gov Identifier: NCT06367907, Retrospectively registered, April 2024.
- 1 May 2022
- Published by Elsevier in Schizophrenia Research
- Vol. 243, 285-295
Neurometabolic patterns of an “at risk for mental disorders” syndrome involve abnormalities in the thalamus and anterior midcingulate cortex
- 1 May 2022
- Published by Elsevier in Schizophrenia Research
- Vol. 243, 285-295
Neurometabolic patterns of an “at risk for mental disorders” syndrome involve abnormalities in the thalamus and anterior midcingulate cortex
- 1 March 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 193, 168-172
Predictors of longer-term outcome in the Vienna omega-3 high-risk study
- 1 March 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 193, 168-172
Predictors of longer-term outcome in the Vienna omega-3 high-risk study
- 1 February 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 227, 688-697
Prefrontal glutamatergic emotion regulation is disturbed in cluster B and C personality disorders – A combined 1H/31P-MR spectroscopic study
- 1 February 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 227, 688-697
Prefrontal glutamatergic emotion regulation is disturbed in cluster B and C personality disorders – A combined 1H/31P-MR spectroscopic study
- 1 October 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 188, 110-117
Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis – Results of the randomized controlled Vienna omega-3 study
- 1 October 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 188, 110-117
Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis – Results of the randomized controlled Vienna omega-3 study
- 1 February 2017
- Published by Elsevier in Neuroscience
- Vol. 343, 423-433
Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence
- 1 February 2017
- Published by Elsevier in Neuroscience
- Vol. 343, 423-433
Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence
- Open Access
- 20 September 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 1-8
Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
The identification of biomarkers of transition from the at-risk mental state (ARMS) to psychotic disorder is important because early treatment of psychosis is associated with improved outcome. Increasing evidence points to an inflammatory contribution to psychosis. We questioned whether raised levels of plasma inflammatory markers predict transition from ARMS to psychotic disorder and whether any such predictors could be reduced by omega-3 (ω-3) polyunsaturated fatty acids (PUFAs). We measured the levels of 40 neuroinflammation biomarkers using a commercially available immunoassay kit. Firstly, we compared inflammatory markers in subjects in the ARMS who transitioned to psychotic disorder (n = 11) compared to subjects who did not (n = 28). Then we compared inflammatory markers in all subjects before and after ω-3 PUFA treatment (n = 40). Our data provides preliminary evidence that elevations in the baseline plasma levels of the inflammatory marker IL12/IL23p40 are associated with transition from ARMS to psychotic disorder. IL12/IL23p40 levels did not change following 12 weeks administration of ω-3 PUFAs. These findings provide evidence that elevated plasma IL12/IL23p40 is a potential biomarker of increased risk for transition to psychotic disorder. Further studies are required to confirm and extend this finding. Our results do not provide support for the possibility that administration of ω-3 PUFAs act to reduced transition to psychotic disorder by reducing blood levels of IL12/IL23p40. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Identifier: NCT00396643 , last updated December 20, 2007. Retrospectively registered.
- 20 September 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 1-8
Open AccessDifferential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
The identification of biomarkers of transition from the at-risk mental state (ARMS) to psychotic disorder is important because early treatment of psychosis is associated with improved outcome. Increasing evidence points to an inflammatory contribution to psychosis. We questioned whether raised levels of plasma inflammatory markers predict transition from ARMS to psychotic disorder and whether any such predictors could be reduced by omega-3 (ω-3) polyunsaturated fatty acids (PUFAs). We measured the levels of 40 neuroinflammation biomarkers using a commercially available immunoassay kit. Firstly, we compared inflammatory markers in subjects in the ARMS who transitioned to psychotic disorder (n = 11) compared to subjects who did not (n = 28). Then we compared inflammatory markers in all subjects before and after ω-3 PUFA treatment (n = 40). Our data provides preliminary evidence that elevations in the baseline plasma levels of the inflammatory marker IL12/IL23p40 are associated with transition from ARMS to psychotic disorder. IL12/IL23p40 levels did not change following 12 weeks administration of ω-3 PUFAs. These findings provide evidence that elevated plasma IL12/IL23p40 is a potential biomarker of increased risk for transition to psychotic disorder. Further studies are required to confirm and extend this finding. Our results do not provide support for the possibility that administration of ω-3 PUFAs act to reduced transition to psychotic disorder by reducing blood levels of IL12/IL23p40. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Identifier: NCT00396643 , last updated December 20, 2007. Retrospectively registered.